Develops gene therapies for blindness and other eye diseases, focusing on innovative treatments and drug delivery systems.
Ocugen, Inc., a dynamic clinical-stage biopharmaceutical firm, specializes in advancing groundbreaking gene therapies aimed at curing debilitating blindness diseases. At the forefront of its innovative pipeline is OCU400, a promising gene therapy designed to restore retinal integrity and function across a spectrum of genetically diverse inherited retinal diseases, including retinitis pigmentosa and leber congenital amaurosis. The company also develops OCU410, a gene therapy candidate targeting dry age-related macular degeneration (AMD), and OCU200, an innovative fusion protein currently in preclinical stages for treating diabetic macular edema, diabetic retinopathy, and wet AMD.
Headquartered in Malvern, Pennsylvania, Ocugen, Inc. operates with a strategic focus on transformative partnerships and collaborations. Notably, the company has established a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Furthermore, Ocugen has joined forces with Bharat Biotech to spearhead the commercialization efforts of COVAXIN, a COVID-19 vaccine, in the United States market. These strategic alliances underscore Ocugen's commitment to leveraging cutting-edge technologies and global partnerships to accelerate the development and delivery of innovative therapies.
Driven by a mission to improve the lives of patients worldwide, Ocugen remains dedicated to advancing the field of gene therapy and biopharmaceutical innovation. With a robust pipeline and a focus on addressing unmet medical needs in ophthalmology, the company continues to push the boundaries of scientific research and therapeutic development to create lasting impact in the healthcare landscape.